Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent

Bibliography

• KANNEL WB, WOLF PA, BENJAMIN EJ, LEVY D: Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: populationbased estimates. Am. J. Cardiol. (1998) 82:2N-9N.
   PubMed Web of Science ®Google Scholar
• FUSTER V, RYDEN LE, ASINGER RW et al.: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American College of the Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology. J. Am. Coll. Cardiol. (2001) 38:1231-1266.
   PubMed Web of Science ®Google Scholar
• WATTIGNEY WA, MENSAH GA, CROFT JB: Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation (2003) 108:711-716.
   PubMed Web of Science ®Google Scholar
• FUSTER V, RYDEN LE, CANNOM DS et al.: ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation (2006) 114:e257-e354.
   PubMed Web of Science ®Google Scholar
• BHANDARI AK, ANDERSON JL, GILBERT EM et al.: Correlation of symptoms with occurrence of paroxysmal supraventricular tachycardia or atrial fibrillation: a transtelephonic monitoring study. The Flecainide Supraventricular Tachycardia Study Group. Am. Heart J. (1992) 124:381-386.
   PubMed Web of Science ®Google Scholar
• GO AS, HYLEK EM, PHILLIPS KA et al.: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA (2001) 285:2370-2375.
   PubMed Web of Science ®Google Scholar
• ROCKSON SG, ALBERS GW: Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. J. Am. Coll. Cardiol. (2004) 43:929-935.
   PubMed Web of Science ®Google Scholar
• WOLF PA, DAWBER TR, THOMAS HE Jr, KANNEL WB: Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham Study. Neurology (1978) 28:973-977.
   PubMed Web of Science ®Google Scholar
• KHAN IA: Atrial stunning: basics and clinical considerations. Int. J. Cardiol. (2003) 92:113-128.
   PubMed Web of Science ®Google Scholar
• MOE GK, RHEINBOLDT WC, ABILDSKOV JA: A computer model of atrial fibrillation. Am. Heart J. (1964) 67:200-220.
   PubMed Web of Science ®Google Scholar
• RENSMA PL, ALLESSIE MA, LAMMERS WJ, BONKE FI, SCHALIJ MJ: Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ. Res. (1988) 62:395-410.
   PubMed Web of Science ®Google Scholar
• LAMMERS WJ, ALLESSIE MA, BONKE FI: Reentrant and focal arrhythmias in low potassium in isolated rabbit atrium. Am. J. Physiol. (1988) 255:H1359-H1369.
   PubMed Web of Science ®Google Scholar
• NATTEL S: New ideas about atrial fibrillation 50 years on. Nature (2002) 415:219-226.
   PubMed Web of Science ®Google Scholar
• BENJAMIN EJ, LEVY D, VAZIRI SM, D’AGOSTINO RB, BELANGER AJ, WOLF PA: Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA (1994) 271:840-844.
   PubMed Web of Science ®Google Scholar
• ALLESSIE MA, BOYDEN PA, CAMM AJ et al.: Pathophysiology and prevention of atrial fibrillation. Circulation (2001) 103:769-777.
   PubMed Web of Science ®Google Scholar
• ORAL H, KNIGHT BP, TADA H et al.: Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. Circulation (2002) 105:1077-1081.
   PubMed Web of Science ®Google Scholar
• LEUNG JM, BELLOWS WH, SCHILLER NB: Impairment of left atrial function predicts post-operative atrial fibrillation after coronary artery bypass graft surgery. Eur. Heart J. (2004) 25:1836-1844.
   PubMed Web of Science ®Google Scholar
• VERBEET T: [Resistant atrial fibrillation: how far does one go in its treatment?]. Rev. Med. Brux. (1999) 20:A237-A244.
   PubMedGoogle Scholar
• WIJFFELS MC, CRIJNS HJ: Rate versus rhythm control in atrial fibrillation. Cardiol. Clin. (2004) 22:63-69.
   PubMed Web of Science ®Google Scholar
• PRYSTOWSKY EN: Assessment of rhythm and rate control in patients with atrial fibrillation. J. Cardiovasc. Electrophysiol. (2006) 17(Suppl. 2):S7-S10.
   Google Scholar
• ROY D, TALAJIC M, DORIAN P et al.: Amiodarone to prevent recurrence of atrial fibrillation. N. Engl. J. Med. (2000) 342:913-920.
   PubMed Web of Science ®Google Scholar
• LEE SH, YU WC, CHENG JJ et al.: Effect of verapamil on long-term tachycardia-induced atrial electrical remodeling. Circulation (2000) 101:200-206.
   PubMed Web of Science ®Google Scholar
• VAN NOORD T, VAN GELDER IC, TIELEMAN RG et al.: VERDICT: the Verapamil versus Digoxin Cardioversion Trial: a randomized study on the role of calcium lowering for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. J. Cardiovasc. Electrophysiol. (2001) 12:766-769.
   Google Scholar
• CORLEY SD, EPSTEIN AE, DI MARCO JP et al.: Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Circulation (2004) 109:1509-1513.
   PubMed Web of Science ®Google Scholar
• HAGENS VE, RANCHOR AV, VAN SONDEREN E et al.: Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J. Am. Coll. Cardiol. (2004) 43:241-247.
   PubMed Web of Science ®Google Scholar
• NATTEL S, OPIE LH: Controversies in atrial fibrillation. Lancet (2006) 367:262-272.
   PubMed Web of Science ®Google Scholar
• MITTAL S, STEIN KM, MARKOWITZ SM, IWAI S, GUTTIGOLI A, LERMAN BB: An update on electrical cardioversion of atrial fibrillation. Cardiol. Electrophysiol. Rev. (2003) 7:285-289.
   Google Scholar
• BORIANI G, BIFFI M, DIEMBERGER I, MARTIGNANI C, BRANZI A: Rate control in atrial fibrillation: choice of treatment and assessment of efficacy. Drugs (2003) 63:1489-1509.
   PubMed Web of Science ®Google Scholar
• ROY D, ROWE BH, STIELL IG et al.: A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J. Am. Coll. Cardiol. (2004) 44:2355-2361.
   PubMed Web of Science ®Google Scholar
• BORIANI G, DIEMBERGER I, BIFFI M, MARTIGNANI C, BRANZI A: Pharmacological cardioversion of atrial fibrillation: current management and treatment options. Drugs (2004) 64:2741-2762.
   PubMed Web of Science ®Google Scholar
• BORIANI G, MARTIGNANI C, BIFFI M, CAPUCCI A, BRANZI A: Oral loading with propafenone for conversion of recent-onset atrial fibrillation: a review on in-hospital treatment. Drugs (2002) 62:415-423.
   PubMed Web of Science ®Google Scholar
• DELL’ORFANO JT, PATEL H, WOLBRETTE DL, LUCK JC, NACCARELLI GV: Acute treatment of atrial fibrillation: spontaneous conversion rates and cost of care. Am. J. Cardiol. (1999) 83:788-790 (A10).
   PubMed Web of Science ®Google Scholar
• NATTEL S: Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs. Cardiovasc. Res. (1998) 37:567-577.
   PubMed Web of Science ®Google Scholar
• WIJFFELS MC, DORLAND R, MAST F, ALLESSIE MA: Widening of the excitable gap during pharmacological cardioversion of atrial fibrillation in the goat: effects of cibenzoline, hydroquinidine, flecainide, and d-sotalol. Circulation (2000) 102:260-267.
   PubMed Web of Science ®Google Scholar
• NATTEL S, HADJIS T, TALAJIC M: The treatment of atrial fibrillation. An evaluation of drug therapy, electrical modalities, and therapeutic considerations. Drugs (1994) 48:345-371.
   PubMed Web of Science ®Google Scholar
• FLAKER GC, BLACKSHEAR JL, MCBRIDE R, KRONMAL RA, HALPERIN JL, HART RG: Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J. Am. Coll. Cardiol. (1992) 20:527-532.
   PubMed Web of Science ®Google Scholar
• MORGANROTH J: Risk factors for the development of proarrhythmic events. Am. J. Cardiol. (1987) 59:32E-37E.
   PubMed Web of Science ®Google Scholar
• KNELLER J, KALIFA J, ZOU R et al.: Mechanisms of atrial fibrillation termination by pure sodium channel blockade in an ionically-realistic mathematical model. Circ. Res. (2005) 96:e35-e47.
   Web of Science ®Google Scholar
• ALLESSIE MA, BONKE FI, SCHOPMAN FJ: Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. The ‘leading circle’ concept: a new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle. Circ. Res. (1977) 41:9-18.
   PubMed Web of Science ®Google Scholar
• MOE GK: A conceptual model of atrial fibrillation. J. Electrocardiol. (1968) 1:145-146.
   PubMedGoogle Scholar
• KIRCHHOF C, WIJFFELS M, BRUGADA J, PLANELLAS J, ALLESSIE M: Mode of action of a new class IC drug (ORG 7797) against atrial fibrillation in conscious dogs. J. Cardiovasc. Pharmacol. (1991) 17:116-124.
   Google Scholar
• KHAN MH: Oral class III antiarrhythmics: what is new? Curr. Opin. Cardiol. (2004) 19:47-51.
   Web of Science ®Google Scholar
• PRYSTOWSKY EN, FREELAND S, BRANYAS NA et al.: Clinical experience with dofetilide in the treatment of patients with atrial fibrillation. J. Cardiovasc. Electrophysiol. (2003) 14:S287-S290.
   Google Scholar
• DESSERTENNE F, COUMEL P, FABIATO A: Ventricular fibrillation and torsades de pointes. Cardiovasc. Drugs Ther. (1990) 4:1177-1182.
   Google Scholar
• CHOY AM, DARBAR D, DELL’ORTO S, RODEN DM: Exaggerated QT prolongation after cardioversion of atrial fibrillation. J. Am. Coll. Cardiol. (1999) 34:396-401.
   PubMed Web of Science ®Google Scholar
• KEREN A, TZIVONI D: Torsades de pointes: prevention and therapy. Cardiovasc. Drugs Ther. (1991) 5:509-513.
   Google Scholar
• FABER TS, ZEHENDER M, JUST H: Drug-induced torsade de pointes. Incidence, management and prevention. Drug Saf. (1994) 11:463-476.
   PubMed Web of Science ®Google Scholar
• STEINBERG JS, SADANIANTZ A, KRON J et al.: Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation (2004) 109:1973-1980.
   PubMed Web of Science ®Google Scholar
• WYSE DG, WALDO AL, DI MARCO JP et al.: A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. (2002) 347:1825-1833.
   PubMed Web of Science ®Google Scholar
• FEDIDA D, ORTH PM, HESKETH JC, EZRIN AM: The role of late INa and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers. J. Cardiovasc. Electrophysiol. (2006) 17(Suppl. 1):S71-S78.
   Google Scholar
• REIFFEL JA: Drug choices in the treatment of atrial fibrillation. Am. J. Cardiol. (2000) 85:12D-19D.
   PubMed Web of Science ®Google Scholar
• HONDEGHEM LM: Computer aided development of antiarrhythmic agents with class IIIa properties. J. Cardiovasc. Electrophysiol. (1994) 5:711-721.
   Google Scholar
• FEDIDA D, ORTH PMR, CHEN JYC et al.: The mechanism of atrial antiarrhythmic action of RSD1235. J. Cardiovasc. Electrophysiol. (2005) 16:1227-1238.
   Google Scholar
• DORIAN P, MANGAT I, KORLEY V, BEATCH GN, CVITKOVIC S, PINTER A: The investigational antiarrhythmic agent RSD1235 is atrially selective in humans. American Heart Association, Dallas, USA (2005):AOP 53.1.
   Google Scholar
• ANNO T, HONDEGHEM LM: Interactions of flecainide with guinea pig cardiac sodium channels. Importance of activation unblocking to the voltage dependence of recovery. Circ. Res. (1990) 66:789-803.
   PubMed Web of Science ®Google Scholar
• SNYDERS DJ, HONDEGHEM LM: Effects of quinidine on the sodium current of guinea pig ventricular myocytes. Evidence for a drug-associated rested state with altered kinetics. Circ. Res. (1990) 66:565-579.
   PubMed Web of Science ®Google Scholar
• WANG GK, RUSSELL C, WANG SY: State-dependent block of wild-type and inactivation-deficient Na+ channels by flecainide. J. Gen. Physiol (2003) 122:365-374.
   PubMed Web of Science ®Google Scholar
• KONZEN G, REICHARDT B, HAUSWIRTH O: Fast and slow blockade of sodium channels by flecainide in rabbit cardiac Purkinje fibres. Naunyn Schmiedebergs Arch. Pharmacol. (1990) 341:565-576.
   PubMed Web of Science ®Google Scholar
• NATTEL S: Atrial electrophysiology and mechanisms of atrial fibrillation. J. Cardiovasc. Pharmacol. Ther. (2003) 8(Suppl. 1):S5-S11.
   Google Scholar
• HUME JR, UEHARA A: Ionic basis of the different action potential configurations of single guinea-pig atrial and ventricular myocytes. J. Physiol. (Camb.) (1985) 368:525-544.
   PubMed Web of Science ®Google Scholar
• CAST INVESTIGATORS: Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N. Engl. J. Med. (1989) 321:406-412.
   PubMed Web of Science ®Google Scholar
• BARRETT TD, HAYES ES, WALKER MJ: Lack of selectivity for ventricular and ischaemic tissue limits the antiarrhythmic actions of lidocaine, quinidine and flecainide against ischaemia-induced arrhythmias. Eur. J. Pharmacol. (1995) 285:229-238.
   PubMed Web of Science ®Google Scholar
• FEDIDA D, WIBLE B, WANG Z et al.: Identity of a novel delayed rectifier current from human heart with a cloned K+ channel current. Circ. Res. (1993) 73:210-216.
   PubMed Web of Science ®Google Scholar
• FENG JL, WIBLE B, LI GR, WANG ZG, NATTEL S: Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ current in cultured adult human atrial myocytes. Circ. Res. (1997) 80:572-579.
   PubMed Web of Science ®Google Scholar
• AMOS GJ, WETTWER E, METZGER F, LI Q, HIMMEL HM, RAVENS U: Differences between outward currents of human atrial and subepicardial ventricular myocytes. J. Physiol. (Lond.) (1996) 491:31-50.
   Google Scholar
• HEIDBÜCHEL H, VEREECKE J, CARMELIET E: Three different potassium channels in human atrium: contribution to the basal potassium conductance. Circ. Res. (1990) 66:1277-1286.
   PubMed Web of Science ®Google Scholar
• VAN WAGONER DR: Electrophysiological remodeling in human atrial fibrillation. Pacing Clin. Electrophysiol. (2003) 26:1572-1575.
   PubMed Web of Science ®Google Scholar
• TRUDEAU MC, WARMKE JW, GANETZKY B, ROBERTSON GA: HERG, a human inward rectifier in the voltage-gated potassium channel family. Science (1995) 269:92-95.
   PubMed Web of Science ®Google Scholar
• SANGUINETTI MC, TRISTANI-FIROUZI M: hERG potassium channels and cardiac arrhythmia. Nature (2006) 440:463-469.
   PubMed Web of Science ®Google Scholar
• THOMAS D, KARLE CA, KIEHN J: The cardiac hERG/IKr potassium channel as pharmacological target: structure, function, regulation, and clinical applications. Curr. Pharm. Des. (2006) 12:2271-2283.
   Web of Science ®Google Scholar
• ROBERTSON GA, JANUARY CT: HERG trafficking and pharmacological rescue of LQTS-2 mutant channels. Handook Exp. Pharmacol. (2006) 171:349-355.
   PubMedGoogle Scholar
• DORIAN P, MANGAT I, KORLEY V, BEATCH GN, CVITKOVIC A, PINTER A: Electrophysiological properties of an atrial selective antiarrhythmic agent, RSD1235, in humans. Can. J. Cardiol. (2004) 20:198D.
   Google Scholar
• PAUL AA, WITCHEL HJ, HANCOX JC: Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. Br. J. Pharmacol. (2002) 136:717-729.
   PubMed Web of Science ®Google Scholar
• HALLMAN K, CARLSSON L: Prevention of class III-induced proarrhythmias by flecainide in an animal model of the acquired long QT syndrome. Pharmacol. Toxicol. (1995) 77:250-254.
   Web of Science ®Google Scholar
• WINDLE JR, GELETKA RC, MOSS AJ, ZAREBA W, ATKINS DL: Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:ΔKPQ mutation. Ann. Noninvasive Electrocardiol. (2001) 6:153-158.
   PubMed Web of Science ®Google Scholar
• KHAN IA, GOWDA RM: Novel therapeutics for treatment of long-QT syndrome and torsade de pointes. Int. J. Cardiol. (2004) 95:1-6.
   PubMed Web of Science ®Google Scholar
• JU YK, SAINT DA, GAGE PW: Inactivation-resistant channels underlying the persistent sodium current in rat ventricular myocytes. Proc. Biol. Sci. (1994) 256:163-168.
   PubMed Web of Science ®Google Scholar
• SAINT DA, JU YK, GAGE PW: A persistent sodium current in rat ventricular myocytes. J. Physiol. (1992) 453:219-231.
   PubMed Web of Science ®Google Scholar
• CLANCY CE, TATEYAMA M, LIU H, WEHRENS XH, KASS RS: Non-equilibrium gating in cardiac Na+ channels: an original mechanism of arrhythmia. Circulation (2003) 107:2233-2237.
   PubMed Web of Science ®Google Scholar
• ORTH PMR, MAK CHK, HESKETH JC, BEATCH GN, EZRIN AM, FEDIDA D: The novel AF conversion agent RSD1235 preferentially blocks a late component of the human heart (hH1) Na+ current active during repolarization. Biophys. J. (2004) 86:135a.
   Google Scholar
• ORTH PM, HESKETH JC, MAK CK et al.: RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. Cardiovasc. Res. (2006) 70:486-496.
   PubMed Web of Science ®Google Scholar
• BEATCH GN, HELMES M, BLAAUW Y et al.: Acute reversal of electrical remodeling and cardioversion of persistent AF by a novel atria – selective antiarrhythmic drug, RSD1235 in the goat. Circulation (2004) 110:III-163.
   Google Scholar
• BEATCH GN, SHINAGAWA K, JOHNSON BD et al.: RSD1235 selectively prolongs atrial refractoriness and terminates AF in dogs with electrically remodelled atria. Pharmacologist (2002) 44(2 Suppl. 1):A15.
   Google Scholar
• BECHARD JP, GIBSON JK, EZRIN AM: The cardiovascular effects of vernakalant in conscious Beagle dogs. Safety Pharmacology Society (2006).
   Google Scholar
• CARLSSON L, ALMGREN O, DUKER G: QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions. J. Cardiovasc. Pharmacol. (1990) 16:276-285.
   Google Scholar
• EZRIN AM, GRANT SM, BELL G et al.: A dose-ranging study for RSD1235, a novel antiarrhythmic agent, in healthy volunteers. Pharmacologist (2002) 44(Suppl. 1):A15.
   Google Scholar
• BEATCH GN, GRANT S, CLOHS L et al.: A novel atrial-selective antiarrhythmic drug, shows rapid and extensive oral absorption in man. International Society of Cardiovascular Pharmacotherapy (2003).
   Google Scholar
• DORIAN P, MANGAT I, KORLEY V, BEATCH GN, CVITKOVIC S, PINTER A: A Phase II study of the investigational antiarrhythmic agent RSD1235 shows that it is atrially selective in humans. J. Cardiovasc. Pharmacol. (2007) (Submitted).
   Google Scholar
• STIELL IG, ROWE BH, ROY D et al.: RSD1235 in the treatment of recent onset atrial fibrillation in ACT 1 (Atrial Arrhythmia Conversion Trial I) – effect of age, sex, and prior rate control medications. Ann. Emerg. Med. (2005) 46:S115.
   PubMed Web of Science ®Google Scholar
• PRATT C, ROY D, JUUL-MOLLER S et al.: Efficacy and tolerance of RSD1235 in the treatment of atrial fibrillation or atrial flutter: results of a Phase III, randomized, placebo-controlled, multicenter trial. Europace (2006) 8:155-153.
   Google Scholar
• ROY D, PRATT C, WYSE DG et al.: Efficacy and safety of RSD1235 in the treatment of recent onset atrial fibrillation in ACT1 (Atrial Arrhythmia Conversion Trial I), a Phase III, randomized, placebo-controlled, multi-center trial. European Society of Cardiology, Stockholm, Sweden (2005).
   Google Scholar
• STIELL IG, ROY D, ROWE BH, PRATT C, DICKINSON G, KITT T: Efficacy and safety of RSD1235 in the treatment of acute atrial fibrillation. Acad. Emerg. Med. (2006) 13(Suppl. 1):S162-a.
   Google Scholar
• CRIJNS HJ: Rate versus rhythm control in patients with atrial fibrillation: what the trials really say. Drugs (2005) 65:1651-1667.
   PubMed Web of Science ®Google Scholar
• TORP-PEDERSEN C, MOLLER M, BLOCH-THOMSEN PE et al.: Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N. Engl. J. Med. (1999) 341:857-865.
   PubMed Web of Science ®Google Scholar
• NERBONNE JM, KASS RS: Molecular physiology of cardiac repolarization. Physiol. Rev. (2005) 85:1205-1253.
   PubMed Web of Science ®Google Scholar